ReviewCurrent opinion in HIV and AIDS2026
Learned young: HIV-1 germline-targeting vaccination in infants.
Review in Current opinion in HIV and AIDS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIt is standard practice to protect infants against viruses that they are exposed to early in life, during childhood, or as adults. While HIV-1 is only rarely a risk in the period between the end of breast-feeding and the onset of sexual maturity, there are good immunological and practical arguments for assessing whether vaccination of young children might be beneficial. RECENT
findingsStudies of HIV-1-infected individuals suggest that the characteristics of the developing immune system may favor the evolution of B cells that produce broadly neutralizing antibodies (bNAbs), when compared to the same processes in adults. One way to exploit these properties of the infant immune system is targeting the germline precursors of B cells that can, over time and with the right sequential antigenic stimuli, mature into bNAb-producing plasma cells. Multidose immunization over time is standard practice within global childhood vaccine frameworks. SUMMARY: We discuss strategies to accomplish the goal of inducing bNAbs, based on the use of specifically designed envelope glycoprotein immunogens. We also summarize how bNAbs may be used for passive protection of infants and combined with active vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.